A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Tanezumab (Primary)
- Indications Osteoarthritis; Pain
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 18 Sep 2017 Planned primary completion date changed from 20 Mar 2018 to 28 Nov 2017.
- 31 Aug 2017 Planned End Date changed from 7 Jun 2018 to 15 May 2018.
- 31 Aug 2017 Planned primary completion date changed from 21 Dec 2017 to 20 Mar 2018.